Skip to main content

Table 1 IC50 values of drugs in glioma tumor-initiating cells and U87 cultured in agarose

From: Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells

Drugs

GSC11

GSC47

GSC20

GSC2

U87

Receptor tyrosine kinase inhibitors

 Erlotinib (μM)

0.11 ± 0.03

0.49 ± 0.15

0.82 ± 0.34

3.08 ± 0.55

3.72 ± 0.60

 Lapatinib (μM)

0.64 ± 0.22

1.86 ± 0.16

4.39 ± 1.08

3.04 ± 0.99

7.01 ± 2.20

 Sorafenib (μM)

2.59 ± 0.50

1.09 ± 0.44

2.21 ± 0.16

3.51 ± 0.25

5.24 ± 0.01

 Imatinib (μM)

6.37 ± 0.90

NE

11.0 ± 1.57

6.28 ± 2.24

3.24 ± 2.10

Non-receptor kinase inhibitors

 U0126 (μM)

14.0 ± 4.72

18.0 ± 3.25

4.69 ± 1.33

11.0 ± 0.25

11.1 ± 5.35

 BKM120 (μM)

0.41 ± 0.05

0.46 ± 0.21

0.36 ± 0.05

0.49 ± 0.10

0.59 ± 0.21

 PP2 (μM)

1.93 ± 0.50

NE

6.39 ± 2.46

4.33 ± 0.34

NA > 20

Transcription factor inhibitors

 WP1066 (μM)

2.46 ± 0.62

NE

1.55 ± 0.13

1.96 ± 0.13

1.59 ± 0.40

 Myc II (μM)

22.3 ± 3.57

NE

13.3 ± 1.50

19.0 ± 3.47

27.0 ± 5.68

DNA cross-linking agent

 BBR3610 (nM)

46.6 ± 23.0

NE

87.3 ± 33.5

117.3 ± 71

1.46 ± 1.26

  1. Data are means ± 95 % confidence intervals of at least two independent experiments
  2. NE Not examined, NA Not available, Myc II c-Myc inhibitor II
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us